ClinicalTrials.gg
Active, not recruitingNCT07853950Updated Oct 2, 2026

Fibrin Clot Augmentation in Arthroscopic Rotator Cuff Repair

An interventional study of Arthroscopic Rotator Cuff Repair and Autologous Fibrin Clot in Rotator Cuff Tears and Rotator Cuff Injuries, sponsored by Ataturk University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Ataturk University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Nov 2025, registered Sep 2026).
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 85 studies in Rotator Cuff Injuries with a site in Turkey — 19 open to participants now, 22 under way, none of them phase 3. Rotator Cuff Injuries · Turkey.

Enrollment
24th of 63
50 · median 44
Started
2025
with 11 others
No phase
63 of 85
11 open now
Primary completion
2027-02
later than 19 of 21 live
Registered
85th of 85
by date

Among the 85 studies in Rotator Cuff Injuries with a site in Turkey, this one is the 24th largest by enrollment of the 63 interventional ones that give a count, is one of 12 that started in 2025, is one of 63 with no phase, reaches primary completion later than 19 of the 21 other live ones, and was the 85th registered.

Rotator Cuff Injuries

632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.

Browse Rotator Cuff Injuries studies →

Open to participants now

19 of the 85 studies in Rotator Cuff Injuries with a site in Turkey are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Rotator Cuff Injuries with a site in Turkey, or all of them as a file.
02

Study summary

The aim of this study is to evaluate whether applying an autologous fibrin clot to the repair site improves tendon healing and clinical outcomes after arthroscopic rotator cuff repair. Fifty patients with rotator cuff tears requiring surgery were randomly assigned to two groups: arthroscopic repair with autologous fibrin clot augmentation or standard arthroscopic repair alone. The fibrin clot is prepared from the patient's own blood without centrifugation. Tendon healing is assessed with magnetic resonance imaging (MRI) using the Sugaya classification at 12 months, and shoulder function and pain are assessed with the ASES score, Constant score and Visual Analog Scale (VAS) preoperatively and at 3, 6 and 12 months.

Read the detailed description

Rotator cuff tears are a common cause of shoulder pain and dysfunction, and retear after surgical repair remains a significant problem. Biological augmentation strategies aim to enhance healing at the tendon-bone interface. Autologous fibrin clot is a simple, low-cost biological augment that provides a fibrin scaffold containing platelets and growth factors, and it can be prepared intraoperatively without centrifugation or commercial kits.

In this prospective, randomized, double-blind controlled trial, 50 patients aged 18-80 years with full-thickness or partial-thickness rotator cuff tears (Goutallier fatty infiltration grade 1 or 2) and an indication for surgical repair were randomly allocated in a 1:1 ratio using a computer-generated randomization sequence to either the fibrin clot group (n=25) or the control group (n=25). Patients and outcome assessors are blinded to group allocation.

In the fibrin clot group, 40 mL of venous blood is drawn from the patient during surgery and stirred with a sterile glass rod until a fibrin clot forms. The clot is then delivered arthroscopically to the tendon-bone repair interface. The control group undergoes the same arthroscopic rotator cuff repair without fibrin clot application. Both groups follow the same postoperative rehabilitation protocol.

The primary outcome is rotator cuff repair integrity evaluated with MRI according to the Sugaya classification at 12 months postoperatively. Secondary outcomes are ASES score, Constant score and VAS pain score, assessed preoperatively and at 3, 6 and 12 months postoperatively.

03

Conditions studied

  • Rotator Cuff Tears
  • Rotator Cuff Injuries

Browse trials for

Keywords

  • Rotator Cuff Repair
  • Fibrin Clot
  • Autologous Fibrin
  • Arthroscopy
  • Biological Augmentation
  • Tendon Healing
  • Retear
  • Sugaya Classification
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 80 years
  • Full-thickness or partial-thickness rotator cuff tear with an indication for arthroscopic surgical repair
  • Goutallier fatty infiltration grade 1 or 2
  • Written

Exclusion criteria

Exclusion Criteria:

  • Massive rotator cuff tear
  • Advanced glenohumeral osteoarthritis
  • Previous open shoulder surgery
  • Serious comorbid disease (e.g., uncontrolled diabetes mellitus, advanced rheumatoid arthritis)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Fibrin Clot Group

    Arthroscopic rotator cuff repair augmented with an autologous fibrin clot applied to the tendon-bone repair interface.

    Procedure: Arthroscopic Rotator Cuff Repair · Biological: Autologous Fibrin Clot

  • Active comparator
    Control Group

    Standard arthroscopic rotator cuff repair without fibrin clot augmentation.

    Procedure: Arthroscopic Rotator Cuff Repair

Interventions

  • ProcedureArthroscopic Rotator Cuff Repair

    Standard arthroscopic repair of the torn rotator cuff tendon to its footprint using suture anchors.

  • BiologicalAutologous Fibrin Clot

    40 mL of venous blood is drawn from the patient during surgery and stirred with a sterile glass rod until a fibrin clot forms, without centrifugation. The clot is delivered arthroscopically to the tendon-bone repair interface.

    Also known as: Endogenous Fibrin Clot

06

What researchers measure

Primary outcomes

  1. Rotator Cuff Repair Integrity on MRI (Sugaya Classification)

    Repair integrity is evaluated with magnetic resonance imaging and classified according to the Sugaya classification (Type I to V). Types I-III are considered healed and Types IV-V are considered retear. The proportion of healed repairs and the retear rate are compared between groups.

    Time frame: 12 months postoperatively

Secondary outcomes

  1. American Shoulder and Elbow Surgeons (ASES) Score

    Patient-reported shoulder pain and function score ranging from 0 to 100, with higher scores indicating better shoulder function.

    Time frame: Preoperatively and at 3, 6 and 12 months postoperatively

Other outcomes

  1. Constant-Murley Score

    Shoulder function score including pain, activities of daily living, range of motion and strength, ranging from 0 to 100, with higher scores indicating better shoulder function.

    Time frame: Preoperatively and at 3, 6 and 12 months postoperatively

  2. Visual Analog Scale (VAS) for Pain

    Shoulder pain intensity measured on a 0-10 scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.

    Time frame: Preoperatively and at 3, 6 and 12 months postoperatively

07

Study locations

1 site
  • Ataturk University Education and Research Hospital
    Erzurum, Erzurum 25240, Turkey (Türkiye)
08

References and documents

Publications

  • Rodeo SA, Delos D, Williams RJ, Adler RS, Pearle A, Warren RF. The effect of platelet-rich fibrin matrix on rotator cuff tendon healing: a prospective, randomized clinical study. Am J Sports Med. 2012 Jun;40(6):1234-41. doi: 10.1177/0363546512442924. Epub 2012 Apr 10. PubMed 22495146 ↗

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared due to patient confidentiality. De-identified data may be made available by the principal investigator upon reasonable request.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.

Of 228 non-industry interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 15 months is below that.

Counting every sponsor, half of 252 studies reached it within 23 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 2, 2026
StartActual
Nov 15, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853950
Lead sponsor
Ataturk University
Responsible party
Ebubekir Safa Budak (Ahmet Emre Paksoy,Associate Professor, Department of Orthopaedics and Traumatology, Ataturk University) — Principal investigator
First posted
Oct 2, 2026
Start date
Nov 15, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Oct 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion